Hongyun Zhao
Affiliations: | 2016 | Chemical Engineering | Rice University, Houston, TX |
| 2016- | Harvard Medical School, Boston, MA, United States |
Google:
"Hongyun Zhao"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| He LN, Li H, Du W, et al. (2023) Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy. Iscience. 26: 107058 |
| Zhao H, Teng D, Yang L, et al. (2022) Myeloid-derived itaconate suppresses cytotoxic CD8 T cells and promotes tumour growth. Nature Metabolism |
| Guan S, Chen X, Chen Y, et al. (2022) FOXM1 variant contributes to gefitinib resistance via activating wnt/β-catenin signal pathway in non-small cell lung cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Zhao H, Luo F, Xue J, et al. (2021) Emerging immunological strategies: recent advances and future directions. Frontiers of Medicine |
| Luo F, Zeng KM, Cao JX, et al. (2021) Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study. Lipids in Health and Disease. 20: 109 |
| Zhu Z, Parikh P, Zhao H, et al. (2021) Targeting immunometabolism of neoplasms by interleukins: A promising immunotherapeutic strategy for cancer treatment. Cancer Letters |
| Zhao H, Swanson KD, Zheng B. (2021) Therapeutic Repurposing of Biguanides in Cancer. Trends in Cancer |
| Zhou T, Zhang L, Liu T, et al. (2020) Myeloid cell leukemia-1 is an important predictor of survival and progression of small cell lung cancer. Annals of Translational Medicine. 8: 1589 |
| Au-Yeung CL, Yeung TL, Achreja A, et al. (2020) ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment. Nature Communications. 11: 3546 |
| Ma Y, Fang W, Zhang Y, et al. (2020) KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small-Cell Lung Cancer. The Oncologist |